Pharmacologic Glycemic Management of Type 2 Diabetes in Adults-2024 Update
Semaglutide Once weekly semaglutide was evaluated in the STEP-1, phase 3, double-blind placebo-controlled study, which enrolled 1,961 adults with a BMI of 30 or greater ( 27 in persons with 1 weight-related coexisting condition), who did not have diabetes
Semaglutide is FDA-approved for type 2 diabetes, so many insurance companies cover it for this use
Statistical analyses were performed using IBM SPSS software, with significance set at p 0.05)
All products are supplied exclusively for lawful in-vitro laboratory research and analytical use
You may also be able to deduct the expense if your doctor diagnosed you with another disease and prescribed a GLP-1 as part of a weight-loss program aimed at treating it